270 related articles for article (PubMed ID: 29316837)
21. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
22. ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.
Hamad N; Bilmon I; Chee L; Henden A; Johnston A; Purtill D; Bajel A; Tey SK; Yeung D; Cole T; Lewis C; Butler J
Intern Med J; 2023 Dec; 53(12):2319-2329. PubMed ID: 38014511
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
Zhang MY; Zhao P; Zhang Y; Wang JS
PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation.
Cheng Q; Tang Y; Liu F; Li X; Fang D
Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005
[TBL] [Abstract][Full Text] [Related]
25. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and feasibility of ruxolitinib in chronic steroid-refractory GVHD in a pediatric intestine transplant.
Ghobrial S; Gonzalez C; Yazigi N; Kaufman S; Matsumoto C; Fishbein T; Hawksworth J; Kroemer A; Khan K
Pediatr Transplant; 2021 May; 25(3):e13836. PubMed ID: 32981124
[TBL] [Abstract][Full Text] [Related]
27. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.
Ren J; Lin K; Xu J; Lu Q; Luo Y; Lin C; Lu J; Weng Y; Zhang Y; Chen Z; Gale RP; Hu J; Yang T
Clin Transplant; 2024 Jan; 38(1):e15195. PubMed ID: 37987525
[TBL] [Abstract][Full Text] [Related]
28. Skin ulcers caused by ruxolitinib in a patient with chronic cutaneous graft-versus-host disease.
Aslan Candır B; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
J Oncol Pharm Pract; 2022 Jun; 28(4):983-985. PubMed ID: 35019785
[TBL] [Abstract][Full Text] [Related]
29. Ruxolitinib as the first post-steroid treatment for acute and chronic graft-versus-host disease.
Algeri M; Becilli M; Locatelli F
Expert Rev Clin Immunol; 2023; 19(11):1299-1313. PubMed ID: 37606511
[TBL] [Abstract][Full Text] [Related]
30. Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients.
Khandelwal P; Teusink-Cross A; Davies SM; Nelson AS; Dandoy CE; El-Bietar J; Marsh RA; Kumar AR; Grimley MS; Jodele S; Myers KC
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1122-1127. PubMed ID: 28344057
[TBL] [Abstract][Full Text] [Related]
31. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
Saraceni F; Scortechini I; Mancini G; Mariani M; Federici I; Gaetani M; Barbatelli P; Minnucci ML; Bagnarelli P; Olivieri A
Transpl Infect Dis; 2021 Feb; 23(1):e13401. PubMed ID: 32629531
[TBL] [Abstract][Full Text] [Related]
32. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
Martini DJ; Chen YB; DeFilipp Z
Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
[TBL] [Abstract][Full Text] [Related]
33. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
Baccelli F; Gottardi F; Muratore E; Leardini D; Grasso AG; Gori D; Belotti T; Prete A; Masetti R
Bone Marrow Transplant; 2024 Jun; 59(6):765-776. PubMed ID: 38402346
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
[TBL] [Abstract][Full Text] [Related]
35. ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.
Penack O; Peczynski C; Boreland W; Lemaitre J; Reinhardt HC; Afanasyeva K; Avenoso D; Holderried TAW; Kornblit BT; Gavriilaki E; Martinez C; Chiusolo P; Mico MC; Dagunet E; Wichert S; Ozdogu H; Piekarska A; Kinsella F; Basak GW; Schoemans H; Koenecke C; Moiseev I; Peric Z
Bone Marrow Transplant; 2024 Mar; 59(3):380-386. PubMed ID: 38184740
[TBL] [Abstract][Full Text] [Related]
36. Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program.
Pattipaka T; Sarp S; Nakhaei P; Güneş S
Bone Marrow Transplant; 2024 May; 59(5):637-646. PubMed ID: 38361117
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges.
Redondo S; Esquirol A; Novelli S; Caballero AC; Garrido A; Oñate G; López J; Moreno C; Saavedra SD; Granell M; Briones J; Sierra J; Martino R; García-Cadenas I
Transplant Cell Ther; 2022 Jan; 28(1):43.e1-43.e5. PubMed ID: 34757054
[TBL] [Abstract][Full Text] [Related]
38. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
[TBL] [Abstract][Full Text] [Related]
39. Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience.
Spałek A; Wieczorkiewicz-Kabut A; Koclęga A; Woźniczka K; Węglarz P; Boral K; Kata D; Zielińska P; Helbig G
Int J Hematol; 2022 Dec; 116(6):922-928. PubMed ID: 35972605
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]